LEADER 01371nam0 22003493i 450 001 CAG0049545 005 20170908093242.0 100 $a20170116d1963 ||||0itac50 ba 101 | $aita 102 $ait 181 1$6z01$ai $bxxxe 182 1$6z01$an 200 1 $aVite parallele$eletture scelte$fPlutarco$gcon introduzione e commento di Giuseppe Ammendola 210 $aNapoli$cA. Rondinella$d1963 215 $a177 p.$d22 cm 300 $aTesto in greco. 676 $a883$9POESIA EPICA E NARRATIVA GRECA CLASSICA$v14 700 0$aPlutarchus$3CFIV005487$4070$0439241 702 1$aAmmendola$b, Giuseppe$f <1878-1955>$3SBLV229223 790 0$aPloytarchoy$3CFIV259063$zPlutarchus 790 0$aPlutarque$3CFIV259064$zPlutarchus 790 0$aPlutarch$3CFIV259065$zPlutarchus 790 0$aPlutarth$3CFIV259066$zPlutarchus 790 0$aPlutarco$3CFIV259071$zPlutarchus 790 0$aPloutarkhos$3SBNV036198$zPlutarchus 801 3$aIT$bIT-NA0079$c20170116 850 $aIT-NA0611 912 $aCAG0049545 950 0$aBIBLIOTECA MARIA D’APONTE$c1 v.$d 43BIBLIOTECA883 PLUT vi$e 43 0000002325 H A4 1 v. Esemplare privo di data in quanto verosimilmente si tratta di stampa preventiva donata al possessore.$fZ $h20090603$i20090603 977 $a 43 996 $aBioi paralleloi$913902 997 $aUNISANNIO LEADER 01388nam0 22003373i 450 001 CAG0101480 005 20170908093252.0 100 $a20110530d2002 ||||0itac50 ba 101 | $aita 102 $ait 105 $a|||| |||a| 181 1$6z01$ai $bxxxe 182 1$6z01$an 200 1 $aAddio alle armi$fErnest Hemingway$gpresentazione, introduzione e traduzione di Fernanda Pivano 210 $aMilano$cCorriere della sera$d2002 215 $a377 p.$d22 cm 225 | $a˜I œgrandi romanzi$v5 300 $aSuppl. a: Corriere della sera. 410 0$1001TSA0435290$12001 $a˜I œgrandi romanzi$v5 500 10$a˜A œfarewell to arms.$3CFI0012179$9CFIV007315$915509 676 $a813.5$9NARRATIVA AMERICANA IN LINGUA INGLESE. 20. SEC.$v12 700 1$aHemingway$b, Ernest$3CFIV007315$4070$0131870 702 1$aPivano$b, Fernanda$3CFIV037838 801 3$aIT$bIT-NA0079$c20110530 850 $aIT-BN0077$aIT-AV0126 912 $aCAG0101480 950 0$aRIBAB - Biblioteca comunale S.Anselmo$d 45GENERALE 813 HEM /2$e 45 0000054565 B $fD $h20110530$i20110530 950 0$aBiblioteca civica "Can. Marciano De Leo"$c1 v.$d FRB 002. 168$e FR 0000006375 B 1 v.$fT $h20120730$i20120730 977 $a 45$a FR 996 $aFarewell to arms$915509 997 $aUNISANNIO LEADER 06341nam 22009733u 450 001 9910139555703321 005 20260217225553.0 010 $a1-283-24049-1 010 $a9786613240491 010 $a1-4443-4257-6 010 $a1-4443-4254-1 035 $a(CKB)2550000000045840 035 $a(EBL)819297 035 $a(OCoLC)759159254 035 $a(SSID)ssj0000633398 035 $a(PQKBManifestationID)12245060 035 $a(PQKBTitleCode)TC0000633398 035 $a(PQKBWorkID)10619848 035 $a(PQKB)11067818 035 $a(MiAaPQ)EBC819297 035 $a(EXLCZ)992550000000045840 100 $a20131104d2011|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aClinical Dilemmas in Inflammatory Bowel Disease $eNew Challenges 205 $a2nd ed. 210 $aHoboken $cWiley$d2011 215 $a1 online resource (286 p.) 300 $aDescription based upon print version of record. 311 08$a1-4443-3454-9 327 $aClinical Dilemmas inInflammatoryBowel Disease; Contents; Contributors; Preface; Part I: Genes and Phenotype in IBD; 1 Which will take us further in IBD-study of coding variation or epigenetics?; 2 IBD in different ethnic groups: same or different?; Part II: Bugs and IBD-Good, Bad, or Indifferent?; 3 How does the risk of infection influence management of IBD around the world?; 4 Traveling with IBD; 5 What to do about hepatitis B and hepatitis C in patients with IBD; 6 CMV in IBD-passenger or pathogen?; 7 Clostridium difficile in IBD: impact, prevention, and treatment 327 $a8 Prebiotics and synbiotics: panacea or placebo9 Worms: light at the end of their burrow; 10 Do we really need to vaccinate all patients with IBD?; Part III: Investigating IBD; 11 Biomarkers in IBD: myth or marvel?; 12 Radiation exposure in IBD: how do we minimize the dangers?; 13 Surveillance colonoscopy in UC: what is the best way to do it?; Part IV: Medical Therapy; 5-ASA; 14 New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward?; 15 Do 5-ASAs prevent cancer?; 16 Why do we still use 5-ASAs in Crohn's disease?; Steroids 327 $a17 Steroids in Crohn's disease: do the benefits outweigh the dangers?Immunomodulators; 18 Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory?; 19 Thiopurines and the sun: what should be done?; 20 Do thiopurines worsen risk and prognosis of cervical neoplasia?; 21 Optimizing use of methotrexate; 22 Which calcineurin inhibitor and when?; Biologics; 23 Are all anti-TNF agents the same?; 24 One drug or two: do patients on biologics need concurrent immunomodulation?; 25 How do we identify patients needing early aggressive therapy and what should we use? 327 $a26 What is the role of biologics in UC?27 What can we do with Crohn's patients who fail or lose response to anti-TNF therapy?; 28 Which extraintestinal manifestations of IBD respond to biologics?; 29 Use and abuse of biologics in pregnancy; 30 Is anti-TNF therapy safe to use in people with a history of malignancy?; 31 The risks of immunomodulators and biologics: what should we tell patients?; 32 When, how, and in whom should we stop biologics?; Part V: Other Treatments; 33 Avoiding drug interactions 327 $a34 Is there still a role for ursodeoxycholic acid treatment patients with inflammatory bowel disease associated with primary sclerosing cholangitis?35 Stem cell transplantation for Crohn's: will it fulfill its promise?; 36 Complementary therapy: is there a needle in the haystack?; Part VI: Surgical Dilemmas in IBD; 37 Optimizing IBD patients for surgery and recovery; 38 Is surgery the best initial treatment for limited ileocecal Crohn's disease?; 39 Laparoscopic or open surgery for IBD?; 40 Optimizing management of perianal Crohn's disease 327 $a41 Does anti-TNF therapy increase the risk of complications of surgery? 330 $aThe second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice. In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking 606 $aClinical dilemmas 606 $aInflammatory bowel diseases 606 $aInflammatory Bowel Diseases 606 $aInflammatory bowel diseases - Decision making 606 $aInflammatory bowel diseases -- Decision making 606 $aInflammatory bowel diseases$xDecision making 606 $aInflammatory bowel diseases 606 $aIntestinal Diseases 606 $aGastroenteritis 606 $aGastrointestinal Diseases 606 $aDigestive System Diseases 606 $aDisease 606 $aInflammatory Bowel Diseases 606 $aMedicine$2HILCC 606 $aHealth & Biological Sciences$2HILCC 606 $aGastroenterology$2HILCC 615 4$aClinical dilemmas. 615 4$aInflammatory bowel diseases. 615 4$aInflammatory Bowel Diseases. 615 4$aInflammatory bowel diseases - Decision making. 615 4$aInflammatory bowel diseases -- Decision making. 615 0$aInflammatory bowel diseases$xDecision making. 615 0$aInflammatory bowel diseases. 615 2$aIntestinal Diseases. 615 2$aGastroenteritis. 615 2$aGastrointestinal Diseases. 615 2$aDigestive System Diseases. 615 2$aDisease. 615 2$aInflammatory Bowel Diseases. 615 7$aMedicine 615 7$aHealth & Biological Sciences 615 7$aGastroenterology 676 $a616.344 700 $aIrving$b Peter$f1970-$0909420 701 $aSiegel$b Corey A$0956257 701 $aRampton$b David$0457140 701 $aShanahan$b Fergus$0909421 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910139555703321 996 $aClinical Dilemmas in Inflammatory Bowel Disease$94543238 997 $aUNINA